Sunday, July 5, 2026
🇺🇸 FDA

QA/QC Tools · GMP · WHO · FDA · EU GMP

GMP Audit Checklist Generator

Interactive GMP audit checklist for WHO GMP, FDA 21 CFR Part 211, EU GMP Annex 1, and EU GMP Part II (API). Pharmaguddu and ISPE publish static checklist articles; this tool adds Pass/Fail/N/A scoring, category filters, and print-ready output.

Quick Answer

A GMP audit checklist is a structured self-inspection tool for pharmaceutical manufacturing covering premises, personnel, documentation, production, QC, and distribution. This generator provides interactive checklists aligned to WHO GMP, FDA 21 CFR Part 211, EU GMP Annex 1 (sterile), and EU GMP Part II (API). Mark items Pass, Fail, or N/A with notes, track compliance percentage, filter by category, and print for mock audits. Internal self-inspections should occur at least annually per EU GMP Chapter 9—not a substitute for regulatory inspection.

0 of 0 items reviewed
Premises & Equipment

Manufacturing areas are maintained clean and orderly

Temperature and humidity are monitored and recorded in all critical areas

HVAC system is validated and maintenance records are current

Cleanroom classification monitoring is performed per schedule

Equipment is cleaned, maintained and qualified (IQ/OQ/PQ records available)

Calibration records for all critical instruments are current

Pest control program is in place and documented

Water system (WFI/Purified Water) is validated and monitored

Personnel

All personnel have documented job descriptions

Training records are current and include GMP training

Personnel health and hygiene requirements are documented and followed

Gowning procedures are documented and staff are trained

Unauthorized persons are prevented from entering manufacturing areas

Documentation

SOPs are current, approved, and version-controlled

SOPs are reviewed at minimum every 2 years

Batch Manufacturing Records (BMRs) are complete and reviewed

Change control procedure is established and followed

Deviation/OOS investigation procedure is in place

CAPA system is operational with follow-up tracking

Document retention policy covers required retention periods

Production

In-process controls are performed and documented

Line clearance is performed and documented before each batch

Reconciliation of yield is performed for each batch

Rejects and returns are handled per written procedures

Starting material release/quarantine system is functioning

Expiry dating and labeling controls are in place

Quality Control

QC laboratory is independent from production

Reference standards are properly stored and documented

Stability study program is in place per ICH Q1A

OOS investigation procedure is followed for all failures

Retained samples program is in place

Certificate of Analysis (CoA) review process is documented

Distribution

Distribution records allow full traceability per batch

Cold chain requirements are documented and monitored

Product recall procedure is documented and tested

Customer complaints are tracked and investigated

Premises & Equipment

21 CFR 211.42: Buildings are of suitable size, construction and location to facilitate cleaning, maintenance, and proper operations

21 CFR 211.63: Equipment used in the manufacture of a drug product is of appropriate design, adequate size, and suitably located

21 CFR 211.68: Automatic, mechanical, or electronic equipment is calibrated, inspected, or checked according to a written program

21 CFR 211.67: Equipment is cleaned and maintained at appropriate intervals to prevent malfunctions or contamination

Personnel

21 CFR 211.25: Personnel have education, training, and experience to perform their assigned functions

21 CFR 211.28: Personnel wear clothing appropriate to the operation, protect drug product from contamination

Documentation

21 CFR 211.68(b): Computer systems are validated, and electronic records/signatures comply with 21 CFR Part 11

21 CFR 211.180: Records are retained for at least 1 year after expiry date (or 3 years after distribution)

21 CFR 211.192: Production record review is completed before batch release

Production

21 CFR 211.110: In-process controls are established and documented for each batch

21 CFR 211.130: Packaging and labeling operations include line clearance and reconciliation

Quality Control

21 CFR 211.165: Each batch is tested for conformity with specifications before release

21 CFR 211.166: Stability testing program is established and data supports expiration dating

21 CFR 211.170: Reserve samples are retained and stored under appropriate conditions

Distribution

21 CFR 211.196: Distribution records are maintained to allow for a recall

21 CFR 211.198: Written procedures for handling of returned drug products are established

Premises & Equipment

Contamination Control Strategy (CCS) document is established and maintained

Cleanroom classification (Grade A/B/C/D) is validated per EN ISO 14644

Environmental monitoring program covers viable and non-viable particle monitoring

Isolator or RABS technology is qualified where used for Grade A operations

WFI system is validated; TOC, conductivity and bioburden monitored

Personnel

Gowning qualification program includes fingertip and glove sampling

Personnel working in Grade A/B areas are regularly monitored for microbial contamination

Production

Aseptic process simulation (media fill) is conducted at required frequency

Sterilization processes (autoclaving, filtration, dry heat, radiation) are validated

Container closure integrity testing is performed and results reviewed

Quality Control

Parametric release program (if applicable) is approved and in compliance

100% visual inspection or validated automatic inspection is performed for parenterals

Premises & Equipment

API manufacturing areas are dedicated or controlled to prevent cross-contamination

Solvent and reagent storage areas meet safety and GMP requirements

Documentation

ICH Q7 compliance: Master batch records exist for all APIs manufactured

Starting material and reagent specifications are documented and approved

Critical process parameters are defined and monitored

Production

Process validation (or verification) covers the entire synthesis route to final API

Impurity profile is established and limits are defined per ICH Q3A

Residual solvents are tested and controlled per ICH Q3C

Quality Control

API specifications include identity, potency, purity and physical parameters

Stability studies for the API are conducted per ICH Q1A with retest date established

Distribution

API containers are properly labelled with retest/expiry date and storage conditions

Chain of custody documentation allows full traceability from raw material to customer

How to Use This Checklist

1
Select the applicable standard tab: WHO GMP, FDA 21 CFR Part 211, EU GMP Annex 1 (sterile), or EU GMP Part II (API).
2
Filter by category—Premises, Personnel, Documentation, Production, QC, or Distribution—to walk one area at a time during the audit.
3
Mark each item Pass, Fail, or N/A. Add notes citing evidence, batch numbers, or N/A justification.
4
Monitor the compliance percentage. Fail items should trigger deviation or CAPA records per site quality SOP.
5
Click Print Checklist to save a PDF for audit files, management review, or supplier audit preparation.

Pharma / GMP Context for QA Professionals

GMP self-inspection is a core element of ICH Q10 pharmaceutical quality systems and EU GMP Chapter 9. Auditors evaluate whether documented procedures match actual manufacturing practice—a gap that frequently surfaces as FDA Form 483 observations. This checklist supports internal audits, supplier qualification visits, and pre-inspection readiness without replacing qualified auditor judgment or regulatory inspection authority.

Multi-standard coverage reflects real-world pharma operations: US sites cite 21 CFR Part 211; EU/UK sites reference EudraLex Volume 4; WHO prequalification and many emerging markets use WHO GMP; API facilities follow ICH Q7 via EU Part II. Sterile manufacturers must additionally assess Annex 1 CCS, environmental monitoring, and aseptic process simulation against the 2022 revision.

Connect audit findings to corrective workflows: open deviations with the Deviation Report Template, escalate systemic issues through the CAPA Template, and verify environmental readiness with Cleanroom Classification and the Audit Readiness Checklist.

Evidence and Sources

Frequently Asked Questions

WHO Good Manufacturing Practice guidelines are international standards published by the World Health Organization for pharmaceutical manufacturing quality assurance. They cover premises, equipment, personnel, documentation, production, and quality control. WHO GMP compliance is required for WHO prequalification of medicines supplied to UN agencies and developing-country procurement programs.
WHO GMP is a global standard widely used in developing countries and for WHO prequalification programs. FDA 21 CFR Part 211 is the US federal regulation for finished pharmaceutical product manufacturers with legally enforceable requirements and FDA inspection authority. Both cover similar principles—premises, personnel, documentation, production, QC—but differ in specific requirements, terminology, citation format, and enforcement mechanisms.
EU GMP Annex 1 (revised August 2022) covers the manufacture of sterile medicinal products. The 2022 revision introduced the Contamination Control Strategy (CCS) as a central requirement and provides detailed requirements for cleanroom grades (A/B/C/D), aseptic processing, environmental monitoring, sterilization, and container closure integrity. It references ISO 14644-1 for particle classification.
Internal GMP self-inspections should be conducted at least annually per WHO and EU GMP Chapter 9. Supplier audits frequency depends on risk assessment—typically annually for critical API or excipient suppliers. Regulatory inspections vary by agency and compliance history, typically every 2–3 years for compliant manufacturers. Major changes trigger immediate re-audit regardless of schedule.
N/A (Not Applicable) means the checklist item does not apply to the facility, process, or product type being audited—for example, sterile Annex 1 items at a solid oral dosage site. Always document the justification for N/A findings in the audit report; inspectors may request rationale during regulatory visits.
Internal GMP audits (self-inspections) are proactive quality system activities conducted by the manufacturer to identify gaps before regulators find them. FDA inspections are regulatory enforcement events with legal authority under 21 CFR, Form 483 observations, and potential Warning Letters. Self-inspection findings should feed CAPA and management review; inspection findings require formal responses within 15 business days.
API manufacturing follows ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), referenced as EU GMP Part II. FDA applies ICH Q7 through guidance and inspection programs for drug substance manufacturers. Finished dosage form sites auditing API suppliers should use Part II/API checklist items covering impurity profiles, process validation, and retest dating—not only 21 CFR Part 211 finished-product requirements.
Standard GMP audit categories include Premises & Equipment, Personnel, Documentation, Production, Quality Control, and Distribution. WHO and FDA checklists emphasize similar domains with different citation styles. Annex 1 adds sterile-specific items: contamination control strategy, environmental monitoring, media fills, and sterilization validation. Filter by category in this tool to focus mock audits on high-risk areas.
WHO prequalification audits assess compliance with WHO GMP, product dossier consistency, and stability data integrity. Prepare by completing a WHO GMP self-inspection using this checklist, ensuring SOPs match actual practice, validating critical equipment, and maintaining traceability from raw material to finished product. Address all Fail findings through CAPA before the inspection window.
The Contamination Control Strategy is a documented, holistic plan linking facility design, personnel, utilities, equipment, processes, and monitoring to prevent microbial and particulate contamination of sterile products. Annex 1 (2022) requires manufacturers to establish, implement, and maintain a CCS and demonstrate its effectiveness during inspections. CCS items appear in the EU GMP Annex 1 tab of this checklist.
Document each Fail finding with evidence, risk classification (Critical/Major/Minor), assigned owner, target closure date, and CAPA reference. Calculate compliance percentage excluding justified N/A items. Attach supporting photos, batch records, or calibration certificates. Management should review the completed checklist in quality review meetings and track overdue corrective actions.
Pair self-inspections with the Audit Readiness Checklist for mock audit simulation, Cleanroom Classification for environmental qualification, Process Capability Cpk for validation data review, RPN Calculator for FMEA risk prioritization under ICH Q9, and CAPA/Deviation templates for closing audit observations. Stability Schedule Generator supports QC laboratory readiness reviews.

Related Tools

☰RPN Calculator 📅Stability Schedule 📋CAPA Template 🏭Cleanroom Classification

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.